Suppr
超能文献

Programmed death-ligand 1 immunohistochemistry testing for non-small cell lung cancer in practice.

作者信息

Mino-Kenudson Mari

机构信息

Department of Pathology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts.

出版信息

Cancer Cytopathol. 2017 Jul;125(7):521-528. doi: 10.1002/cncy.21873. Epub 2017 May 4.

DOI:10.1002/cncy.21873

PMID:28472551

Abstract

摘要

相似文献

Programmed death-ligand 1 immunohistochemistry testing for non-small cell lung cancer in practice.

Cancer Cytopathol. 2017 Jul;125(7):521-528. doi: 10.1002/cncy.21873. Epub 2017 May 4.

Programmed death-ligand 1 testing in patients with non-small cell lung cancer: Ready for prime time?

Cancer Cytopathol. 2017 Aug;125(8):591-593. doi: 10.1002/cncy.21882. Epub 2017 Jun 16.

Programmed death ligand 1 testing: is there one best test?

Clin Adv Hematol Oncol. 2017 Jun;15(6):438-440.

PD-L1 Expression as a Predictive Biomarker: Is Absence of Proof the Same as Proof of Absence?

JAMA Oncol. 2016 Jan;2(1):54-5. doi: 10.1001/jamaoncol.2015.3782.

[Quiz: Ready, study, score!].

Ann Pathol. 2017 Feb;37(1):7-10. doi: 10.1016/j.annpat.2016.12.014. Epub 2017 Feb 1.

Interlaboratory concordance of PD-L1 immunohistochemistry for non-small-cell lung cancer.

Histopathology. 2018 Feb;72(3):449-459. doi: 10.1111/his.13375. Epub 2017 Nov 21.

How to Validate Predictive Immunohistochemistry Testing in Pathology? A Practical Approach Exploiting the Heterogeneity of Programmed Death Ligand-1 Present in Non-Small Cell Lung Cancer.

Arch Pathol Lab Med. 2019 Jan;143(1):11-12. doi: 10.5858/arpa.2018-0410-ED. Epub 2018 Oct 11.

PD-L1 Antibody Comparison in Urothelial Carcinoma.

Eur Urol. 2019 Mar;75(3):538-540. doi: 10.1016/j.eururo.2018.11.002. Epub 2018 Nov 27.

Programmed cell death ligand 1 as a biomarker in head and neck cancer.

Cancer Cytopathol. 2017 Jul;125(7):529-533. doi: 10.1002/cncy.21872. Epub 2017 May 4.

Intra- and Interobserver Reproducibility Assessment of PD-L1 Biomarker in Non-Small Cell Lung Cancer.

Clin Cancer Res. 2017 Aug 15;23(16):4569-4577. doi: 10.1158/1078-0432.CCR-17-0151. Epub 2017 Apr 18.

引用本文的文献

PD-L1 in Cytological Samples: A Review and a Practical Approach.

Front Med (Lausanne). 2021 May 7;8:668612. doi: 10.3389/fmed.2021.668612. eCollection 2021.

Implementation of PD-L1 22C3 IHC pharmDxTM in Cell Block Preparations of Lung Cancer: Concordance with Surgical Resections and Technical Validation of CytoLyt® Prefixation.

Acta Cytol. 2020;64(6):577-587. doi: 10.1159/000508628. Epub 2020 Jun 29.

[Cytology of primary lung cancer].

Pathologe. 2020 Feb;41(1):32-38. doi: 10.1007/s00292-019-00745-z.

Histology versus cytology: PD-L1 testing in non-small cell lung cancer.

Transl Lung Cancer Res. 2018 Sep;7(Suppl 3):S225-S227. doi: 10.21037/tlcr.2018.08.08.

PD-L1 testing using the clone 22C3 pharmDx kit for selection of patients with non-small cell lung cancer to receive immune checkpoint inhibitor therapy: are cytology cell blocks a viable option?

J Am Soc Cytopathol. 2018 May-Jun;7(3):133-141. doi: 10.1016/j.jasc.2018.02.003. Epub 2018 Feb 16.

Immunohistochemistry for predictive biomarkers in non-small cell lung cancer.

Transl Lung Cancer Res. 2017 Oct;6(5):570-587. doi: 10.21037/tlcr.2017.07.06.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

Suppr超能文献

Programmed death-ligand 1 immunohistochemistry testing for non-small cell lung cancer in practice.

作者信息

机构信息

出版信息

相似文献

引用本文的文献

文献AI研究员

用中文搜PubMed

文档翻译